# Efficacy and Safety Evaluation of Octreotide in the Treatment of Congenital Hyperinsulinemia

> **NCT05171751** · — · COMPLETED · sponsor: **Beijing Children's Hospital** · enrollment: 50 (actual)

## Conditions studied

- Congenital Hyperinsulinaemic Hypoglycaemia
- Octreotide Adverse Reaction

## Interventions

- **DRUG:** Octreotide Injection

## Key facts

- **NCT ID:** NCT05171751
- **Lead sponsor:** Beijing Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-01
- **Primary completion:** 2021-12-18
- **Final completion:** 2021-12-18
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2021-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05171751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05171751, "Efficacy and Safety Evaluation of Octreotide in the Treatment of Congenital Hyperinsulinemia". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT05171751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*